Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Summary

In 322 patients with EGFR-variant nonsquamous NSCLC after EGFR-TKI therapy, ivonescimab plus pemetrexed/carboplatin significantly improved overall survival versus chemotherapy alone (median 16.8 vs 14.1 months; HR 0.74; P=0.02). Thirty-month survival was higher with ivonescimab (29.1% vs 18.4%), with more grade ≥3 adverse events but an acceptable safety profile.

Key Findings

• Ivonescimab plus chemotherapy improved median overall survival to 16.8 months versus 14.1 months (HR 0.74; 95% CI, 0.58-0.95; P=.02).
• Estimated 30-month survival was higher with ivonescimab (29.1% vs 18.4%).
• Grade ≥3 treatment-emergent adverse events occurred more frequently with ivonescimab (67.1% vs 54.7%) but were considered acceptable.

Clinical Implications

For EGFR-variant NSCLC progressing after EGFR-TKIs, adding ivonescimab to pemetrexed/carboplatin offers an evidence-based option to improve survival, warranting consideration in treatment algorithms, with careful AE monitoring.

Limitations

• Conducted exclusively in China, which may limit generalizability across ethnic and healthcare settings
• Higher incidence of grade ≥3 adverse events with ivonescimab requiring vigilant monitoring

Future Directions

Head-to-head comparisons with other post-TKI regimens, biomarker stratification (e.g., PD-L1/VEGF signatures), and global trials to validate efficacy and safety across populations.